Developer docs
API playgroundTry for free, no card

Search company profiles

Clarus Therapeutics

Full company profile

uuid0002g2u

Namestring
Clarus Therapeutics
Legal namestring
Clarus Therapeutics Holdings, Inc.
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. Founded in 2003 and headquartered in Northbrook, Illinois, the company operates as a publicly traded entity on NASDAQ under the ticker CRXT, with a headcount of 11-50 employees.

The company's commercial product is JATENZO, an FDA-approved oral softgel capsule formulation of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism (low testosterone). The product is differentiated by its oral route of administration, offering an alternative to traditional injectable testosterone therapies. JATENZO is the only product in Clarus's commercial offering according to available source data, and represents the company's primary revenue-generating asset through prescription pharmaceutical sales.

Clarus commercializes JATENZO via a sales-led go-to-market motion targeting healthcare providers and patients, with the product distributed through traditional pharmacy and specialty pharmacy channels under prescription. The company has financed its operations and commercialization through multiple funding rounds totaling approximately $122 million since 2004, including a $15 million private placement in December 2021 and a $30 million public offering of stock and warrants in April 2022, both explicitly directed at JATENZO commercialization and working capital. The capital cadence and continued reliance on primary financing indicate the company is in an early commercial stage.

Short descriptiontext

Clarus Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: CRXT) that develops and commercializes JATENZO, an FDA-approved oral testosterone replacement therapy for men with hypogonadism, distributed through pharmacy channels under prescription.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNorthbrook, United States
HQ citystring
Northbrook
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oral testosterone therapy, hypogonadism treatment, androgen replacement drugs, men's health pharmaceuticals, testosterone undecanoate capsules
Industry1 code
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
Product category
Men's Health Pharmaceuticals / Testosterone Replacement Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1JATENZO Product Sales
TypeOthers
Description

Revenue generated from sales of JATENZO, an FDA-approved oral testosterone product for men with low testosterone. The company commercialized this product following FDA approval, with $15 million raised in December 2021 specifically to support commercialization activities.

globenewswire.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1JATENZO
Description

Oral testosterone product for the treatment of hypogonadism in men.

globenewswire.com
Core offering1 text field

Clarus Therapeutics develops and commercializes androgen-based prescription pharmaceuticals, with its primary product being JATENZO, an FDA-approved oral softgel capsule of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism. The company focuses on the U.S. commercialization of this single oral testosterone product as an alternative to traditional injectable testosterone therapies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Clarus Therapeutics is a pharmaceutical company that offers JATENZO, an oral testosterone product. The company focuses on the commercialization of this single product for treating hypogonadism in men.

Product and service1 record
1JATENZO
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Besins licenses and markets AndroGel (testosterone gel) outside the U.S., operating in the same TRT category and androgen-replacement therapeutic area as Clarus.

TypeBroad incumbent
Description

AbbVie (via legacy Allergan) markets AndroGel, the leading topical testosterone gel for hypogonadism — a broad incumbent whose TRT franchise competes for the same prescriptions as JATENZO.

TypeDirect peer
Description

Marius commercializes Kyzatrex, an oral testosterone undecanoate product for adult male hypogonadism — the closest direct head-to-head competitor to Clarus's JATENZO in the same product category and patient population.

TypeBroad incumbent
Description

Ferring is a reproductive-health and urology-focused pharmaceutical incumbent with adjacent hormone-replacement assets, making it a relevant comparator in the broader andrology/endocrine space Clarus addresses.

TypeDirect peer
Description

Tolmar markets Xyosted (auto-injector testosterone enanthate) for hypogonadism and also co-developed TLANDO, placing it as a direct competitor to Clarus in the TRT replacement therapy category.

TypeBroad incumbent
Description

Viatris (formed from Mylan/Pfizer Upjohn) distributes generic and branded testosterone products including injectable testosterone enanthate and cypionate, competing in the same male hypogonadism prescription market as JATENZO.

TypeBroad incumbent
Description

Endo markets Aveed (injectable testosterone undecanoate) and previously competed in TRT broadly, making it an established incumbent competing with Clarus in the same male hypogonadism market.

8Acerus Pharmaceuticals
TypeDirect peer
Description

Acerus markets Natesto, a nasal testosterone product for hypogonadism, competing with JATENZO in the non-injectable, non-topical TRT segment.

TypeEmerging player
Description

Lipocine is developing oral testosterone products (LPCN 1144, Tlando) for liver-related and hypogonadism indications, making it an emerging competitor in the oral testosterone space relevant to Clarus.

TypeDirect peer
Description

Antares developed TLANDO, another oral testosterone undecanoate product approved for hypogonadism, making it a direct same-mechanism competitor to JATENZO in the oral TRT category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clarus Therapeutics

Men's Health Pharmaceuticals / Testosterone Replacement Therapyclarustherapeutics.com

Clarus Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: CRXT) that develops and commercializes JATENZO, an FDA-approved oral testosterone replacement therapy for men with hypogonadism, distributed through pharmacy channels under prescription.

What Clarus Therapeutics does

Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. Founded in 2003 and headquartered in Northbrook, Illinois, the company operates as a publicly traded entity on NASDAQ under the ticker CRXT, with a headcount of 11-50 employees.

The company's commercial product is JATENZO, an FDA-approved oral softgel capsule formulation of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism (low testosterone). The product is differentiated by its oral route of administration, offering an alternative to traditional injectable testosterone therapies. JATENZO is the only product in Clarus's commercial offering according to available source data, and represents the company's primary revenue-generating asset through prescription pharmaceutical sales.

Clarus commercializes JATENZO via a sales-led go-to-market motion targeting healthcare providers and patients, with the product distributed through traditional pharmacy and specialty pharmacy channels under prescription. The company has financed its operations and commercialization through multiple funding rounds totaling approximately $122 million since 2004, including a $15 million private placement in December 2021 and a $30 million public offering of stock and warrants in April 2022, both explicitly directed at JATENZO commercialization and working capital. The capital cadence and continued reliance on primary financing indicate the company is in an early commercial stage.

Clarus Therapeutics firmographics

Firmographics
Name
Clarus Therapeutics
Legal name
Clarus Therapeutics Holdings, Inc.
Website
https://clarustherapeutics.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Clarus Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: CRXT) that develops and commercializes JATENZO, an FDA-approved oral testosterone replacement therapy for men with hypogonadism, distributed through pharmacy channels under prescription.
Ownership category
akta.pro rank

Clarus Therapeutics industry classification

Industry
Product category
Men's Health Pharmaceuticals / Testosterone Replacement Therapy
NAICS
Pharmaceutical Preparation Manufacturing (325412)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oral testosterone therapy
  • Hypogonadism treatment
  • Androgen replacement drugs
  • Men's health pharmaceuticals
  • Testosterone undecanoate capsules

Where Clarus Therapeutics is headquartered

Location

Headquarters

HQ city
Northbrook
HQ country
United States
HQ region
North America

Markets served

Clarus Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

  1. JATENZO Product Sales: Revenue generated from sales of JATENZO, an FDA-approved oral testosterone product for men with low testosterone. The company commercialized this product following FDA approval, with $15 million raised in December 2021 specifically to support commercialization activities.

Go-to-market motion1 record

Distribution channels1 record

Clarus Therapeutics product offering

Product offering

Core offering

Clarus Therapeutics develops and commercializes androgen-based prescription pharmaceuticals, with its primary product being JATENZO, an FDA-approved oral softgel capsule of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism. The company focuses on the U.S. commercialization of this single oral testosterone product as an alternative to traditional injectable testosterone therapies.

Product overview

Clarus Therapeutics is a pharmaceutical company that offers JATENZO, an oral testosterone product. The company focuses on the commercialization of this single product for treating hypogonadism in men.

Differentiator

Problem solved

Functional benefit

Brands

  • JATENZO: Oral testosterone product for the treatment of hypogonadism in men.

Products and services

  • JATENZO

Companies that use Clarus Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Clarus Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Clarus Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Clarus Therapeutics competitors and assessment

Company assessment

Direct peers

  • Besins Healthcare: Besins licenses and markets AndroGel (testosterone gel) outside the U.S., operating in the same TRT category and androgen-replacement therapeutic area as Clarus.
  • Marius Pharmaceuticals: Marius commercializes Kyzatrex, an oral testosterone undecanoate product for adult male hypogonadism — the closest direct head-to-head competitor to Clarus's JATENZO in the same product category and patient population.
  • Tolmar Pharmaceuticals: Tolmar markets Xyosted (auto-injector testosterone enanthate) for hypogonadism and also co-developed TLANDO, placing it as a direct competitor to Clarus in the TRT replacement therapy category.
  • Acerus Pharmaceuticals: Acerus markets Natesto, a nasal testosterone product for hypogonadism, competing with JATENZO in the non-injectable, non-topical TRT segment.
  • Antares Pharma (now part of Halozyme): Antares developed TLANDO, another oral testosterone undecanoate product approved for hypogonadism, making it a direct same-mechanism competitor to JATENZO in the oral TRT category.

Broad incumbents

  • AbbVie: AbbVie (via legacy Allergan) markets AndroGel, the leading topical testosterone gel for hypogonadism — a broad incumbent whose TRT franchise competes for the same prescriptions as JATENZO.
  • Ferring Pharmaceuticals: Ferring is a reproductive-health and urology-focused pharmaceutical incumbent with adjacent hormone-replacement assets, making it a relevant comparator in the broader andrology/endocrine space Clarus addresses.
  • Viatris: Viatris (formed from Mylan/Pfizer Upjohn) distributes generic and branded testosterone products including injectable testosterone enanthate and cypionate, competing in the same male hypogonadism prescription market as JATENZO.
  • Endo International (Endo Pharmaceuticals): Endo markets Aveed (injectable testosterone undecanoate) and previously competed in TRT broadly, making it an established incumbent competing with Clarus in the same male hypogonadism market.

Emerging players

  • Lipocine: Lipocine is developing oral testosterone products (LPCN 1144, Tlando) for liver-related and hypogonadism indications, making it an emerging competitor in the oral testosterone space relevant to Clarus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Clarus Therapeutics social profiles

Digital presence

Clarus Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clarus Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Clarus Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clarus Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clarus Therapeutics

What does Clarus Therapeutics do?

Clarus Therapeutics develops and commercializes androgen-based prescription pharmaceuticals, with its primary product being JATENZO, an FDA-approved oral softgel capsule of testosterone undecanoate indicated for testosterone replacement therapy in adult men with hypogonadism. The company focuses on the U.S. commercialization of this single oral testosterone product as an alternative to traditional injectable testosterone therapies.

Is Clarus Therapeutics a public or private company?

Clarus Therapeutics is a public company. It is classified as public and is currently operating.

When was Clarus Therapeutics founded?

Clarus Therapeutics was founded in 2004. It employs 11 to 50 people.

Where is Clarus Therapeutics based?

Clarus Therapeutics is headquartered in Northbrook, United States, in the North America region.

How does Clarus Therapeutics make money?

One revenue line is on record: JATENZO Product Sales.

Who are Clarus Therapeutics's main competitors?

Direct peers on record are Besins Healthcare, Marius Pharmaceuticals, Tolmar Pharmaceuticals, Acerus Pharmaceuticals and Antares Pharma (now part of Halozyme). Broad incumbents are AbbVie, Ferring Pharmaceuticals, Viatris and Endo International (Endo Pharmaceuticals). Lipocine is listed as an emerging player.

Does Clarus Therapeutics have an API?

No public API is recorded for Clarus Therapeutics.

What industry is Clarus Therapeutics in?

Clarus Therapeutics's product category is Men's Health Pharmaceuticals / Testosterone Replacement Therapy. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireClarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful BidderClarus Therapeutics Holdings announced that Tolmar, Inc. won a court-supervised auction for the sale of JATENZO (testosterone undecanoate capsules) on October 14, 2022. The sale remains subject to final Bankruptcy Court approval on October 26, 2022.GlobeNewswireClarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful BidderClarus Therapeutics Holdings, Inc. announced that Tolmar, Inc. was selected as the winning bidder in a court-supervised auction for Clarus's JATENZO product and related assets. The sale is subject to final approval by the U.S. Bankruptcy Court for the District of Delaware on October 26, 2022. This transaction occurs within the context of Clarus's ongoing Chapter 11 bankruptcy proceedings.GlobeNewswireDelisting of Securities of Renovare Environmental, Inc.; Endo International plc; Clarus Therapeutics Holdings, Inc.; NewAge, Inc.; and Allena Pharmaceuticals, Inc. from The Nasdaq Stock MarketNasdaq announced delistings for Renovare Environmental, Endo International, Clarus Therapeutics, NewAge, and Allena Pharmaceuticals, all of which had been suspended and not traded since June to September 2022. The delistings will take effect ten days after Nasdaq files Form 25 with the SEC.BioSpaceClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeClarus Therapeutics Holdings filed Chapter 11 bankruptcy petitions in Delaware and sought court approval to auction its sole commercial asset, JATENZO. The bidding process is projected to conclude late October 2022, with the company citing insufficient financial resources to continue commercialization.GlobeNewswireClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeClarus Therapeutics Holdings filed voluntary Chapter 11 petitions in Delaware and sought court approval to auction its sole commercial asset, JATENZO. The company believes it has sufficient resources to meet obligations during the process. The sale would be free and clear of indebtedness and certain liabilities.GlobeNewswireClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeClarus Therapeutics Holdings filed voluntary Chapter 11 petitions in Delaware and sought court approval to auction its sole commercial asset, JATENZO, for treatment of testosterone deficiency. The company believes it has sufficient resources to meet obligations during the process. The sale would be free and clear of indebtedness and certain liabilities.BenzingaHere's Why Clarus Therapeutics Stock Is Getting ObliteratedClarus Therapeutics Holdings Inc (NASDAQ:CRXT) stock fell 32.24% to $0.14 after receiving a non-compliance letter from Nasdaq regarding failure to meet listing requirements. The company will be suspended from Nasdaq on August 31st and moved to the OTC Pink Market. Clarus failed to meet the $15 million minimum market value of publicly held shares and the $50 million minimum market value of listed securities thresholds, despite being given 180 days until August 17th to regain compliance.BioSpaceClarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce ReductionClarus Therapeutics reported Q2 2022 net revenue of $4.1 million, up 46% year-over-year, and a 40% workforce reduction. The company also announced a new CFO and terminated a research agreement. It stated its cash will fund operations into September 2022.PR NewswireThinking about buying stock in Statera Biopharma, Nokia, Borqs Technologies, Clarus Therapeutics, or Blend Labs?InvestorsObserver issued PriceWatch Alerts for stocks including Statera Biopharma, Nokia, Borqs Technologies, Clarus Therapeutics, and Blend Labs. The alerts are generated using a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. InvestorsObserver provides these investing tools to both institutional investors on Wall Street and self-directed retail investors.